Due Date: April 6, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Joo Young Chung et al.

Examiner.

L. Spector

Serial No.:

09/720,410

Group Art Unit:

1647

Filed:

December 21, 2000

Docket

G&C 118.7-US-WO

Title:

A NOVEL HUMAN THROMBOPOIETIN MUTEIN

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on April 8, 2002.

Name: Karen S. Canady

AMENDMENT UNDER 37 C.F.R. §1.111 AND RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated February 6, 2002, please amend the above-identified application as follows. Please note that, in compliance with the new rules under 37 C.F.R. § 1.121, the amended claims are presented in "clean" form with marked-up versions provided in Appendix A.

IN THE CLAIMS

Please amend claim 1 as follows:

1. (TWICE AMENDED) A human thrombopoietin derivative which is derived from human thrombopoietin (hTPO) described by SEQ ID NO: 30; which elicits approximately equal or greater biological activity as compared to native hTPO; which has at least one additional N-linked glycosylation site; and which is selected from the group consisting of:

[Asn¹⁰⁸] hTPO;

-1-

G&C 118.7-US-WO